



(51) International Patent Classification:

A61K 31/427 (2006.01) A61P 19/06 (2006.01)
C07D 417/12 (2006.01)

(21) International Application Number:

PCT/IB2012/055760

(22) International Filing Date:

19 October 2012 (19.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/549,823 21 October 2011 (21.10.2011) US
61/700,582 13 September 2012 (13.09.2012) US

(71) Applicant: **PFIZER LIMITED** [GB/GB]; Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(72) Inventors: **ALI, Zahid**; c/o Neusentis, Portway Building, Granta Park, Great Abington Cambridge CB21 6GP (GB). **BUTCHER, Kenneth John**; c/o Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **BUTT, Richard Philip**; c/o Neusentis, Portway Building, Granta Park, Great Abington Cambridge CB21 6GP (GB). **FELSTEAD, Stephen John**; c/o Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB). **GLATT, Sophie**; c/o Neusentis, Portway Building, Granta Park, Great Abington Cambridge CB21 6GP (GB). **MCKERNAN, Ruth Mitchell**; c/o Neusentis, Portway Building, Granta Park, Great Abington Cambridge CB21 6GP (GB). **PANESAR, Maninder**; c/o Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(74) Agent: **DROUIN, Stephane**; Pfizer Limited, Ramsgate Road, Sandwich Kent CT13 9NJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: NEW SALT AND MEDICAL USE

(57) Abstract: The invention provides 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide or a pharmaceutically acceptable salt thereof for the treatment of a disease associated with elevated blood uric acid levels, such as hyperuricemia or gout. In another aspect the invention provides the tosylate salt of 4-[2-(5-amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-(1,3-thiazol-4-yl)benzenesulfonamide.

